Wendy L. Wright, MS, ARNP, FNP, FAANP
Adult/Family Nurse Practitioner
Partner, Partners in Healthcare Education, LLC
Bedford, NH 03110
W. Lane Edwards, Jr., MSN, ARNP, ANP
Partner, Partners in Healthcare Education, LLC
Ft Myers, FL 33908
Nurse practitioners 1.2 contact hours (based on a 50-minute hour) which includes 0.8 contact hours of pharmacology credit
Cardiovascular disease (CVD), an umbrella term that encompasses coronary artery disease (CAD) and other diseases of the heart as well as stroke, is the leading killer of both men and women in the US and all Westernized countries. The American Heart Association estimates that 1 in 3 adults has some form of CVD. Since 1900, CVD has been the number 1 killer in the US every year except 1918, when an influenza pandemic claimed more lives. This translates to nearly 2,500 deaths due to CVD each day, for an everage of 1 death every 35 seconds. The largest number of deaths (more than 13 million annually) are due to CAD, which includes myocardial infarction and angina pectoris.
Four common and highly prevalent conditions are inextricably linked to the etiology of CAD. These are dyslipidemia, hypertension, diabetes, and obesity. Fortunately, all of these conditions often can be successfully managed through positive and consistent lifestyle changes. Failing this, there are many efficacious pharmacologic options that can reduce the risk of myocardial infarction and other cardiovascular events.
There is clear evidence that lowering LDL cholesterol, controlling diabetes, and reducing rates of hypertension and obesity will decrease the incidence of CAD and major vascular events. Primary care providers need to understand the risk factors associated with CVD and have the ability to screen and diagnose those patients at risk and develop strategies for managing risk factors. With these goals in mind, this activity will provide information on the topic of CAD mortality caused by dyslipidemia, hypertension, diabetes, and obesity. An overview of recent guidelines, as well as diagnosis and treatment strategies of the “fatal four” conditions leading to CAD, will contribute toward this audience’s overall knowledge on this topic and ability to better treat their patients.
. Target Audience
This program has been designed for nurse practitioners who have an interest in better understanding CAD.
Upon completion of this educational activity, the participant should be able to:
Delineate the roles of dyslipidemia, diabetes, hypertension, and obesity in the development of CAD.
Identify interventions—-both lifestyle-related and pharmacologic—-that can minimize the impact of CAD risk factors.
List the major evidence-based clinical guidelines in the areas of cholesterol, diabetes, hypertension, and obesity.
Formulate a strategy for enhancing patient adherence to lifestyle and pharmacologic treatment regimens.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Wendy Wright has been a member of the speakers bureau for AstraZeneca, Pfizer Inc, GlaxoSmithKline, Kos Pharmaceuticals, Inc., OmniCare, Inc., Roche Pharmaceuticals, and EXACT Sciences Corp. She has received grant funding from AstraZeneca, OmniCare, Inc., Roche Pharmaceuticals, and GlaxoSmithKline.
W. Lane Edwards, Jr., has been a member of the speakers bureau for Kos Pharmaceuticals, Inc., Merck and Co., Inc., Schering-Plough Corp., AstraZeneca, Pfizer Inc, and sanofi aventis. He participated on advisory committees for OmniCare, Inc., AstraZeneca, and sanofi aventis and has received grant funding from AstraZeneca, Kos Pharmaceuticals, Inc., OmniCare, Inc., GlaxoSmithKline, and Roche Pharmaceuticals.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
AKH Inc. is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. Provider number 030803. AKH Inc. designates this educational activity for 1.2 contact hours which includes 0.8 contact hours of pharmacology credit (based on a 50-minute hour)
Commercial Support Statements
Supported by an educational grant from AstraZeneca
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
Complete the short survey and click on "done."
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. This activity will require approximately 60 minutes to complete.
After the program has finished, click on the "Post-test" button. Complete the short survey and click on "done."
Instructions for completing and submitting the post-test and program evaluation are provided on the post-test screen. A credit certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.
The information contained in this program does not necessarily reflect the opinions or recommendations of AstraZeneca, AKH Inc., or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patients’ conditions and possible contraindications or risks, and without a review of applicable manufacturer’s product information and comparison with recommendations of other authorities.